Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 50,746 | 53,814 | 16,880 | 20,111 |
| Short-term investments | 10,276 | 9,993 | 11,913 | 6,160 |
| Accounts receivable | 7,139 | 14,564 | 42,716 | 4,281 |
| Unbilled receivable from government contracts | 50,435 | 36,781 | 43,229 | 36,781 |
| Prepaid expenses and other current assets | 13,108 | 20,971 | 2,632 | 3,046 |
| Total current assets | 131,704 | 136,123 | 117,370 | 70,379 |
| Property and equipment, gross | 19,385 | 19,234 | NaN | NaN |
| Less accumulated depreciation | 14,558 | 13,801 | NaN | NaN |
| Property and equipment, net | 4,827 | 5,433 | 6,064 | 6,926 |
| Prepaid clinical services, long-term | 25,218 | 25,218 | 60,116 | 60,116 |
| Right-of-use assets, net | 10,642 | 11,432 | 17,097 | 18,137 |
| Intangible assets, net | 2,643 | 2,826 | 3,009 | 3,192 |
| Goodwill | 4,508 | 4,508 | 4,508 | 4,508 |
| Other long-term assets | 513 | 539 | 824 | 827 |
| Total assets | 180,055 | 186,079 | 208,988 | 164,085 |
| Accounts payable | 24,185 | 21,496 | 53,075 | 10,611 |
| Deferred revenue-Government Contract | 23 | 68 | 64,828 | 65,377 |
| Deferred revenue-Collaboration Revenue | 11,716 | 12,952 | NaN | NaN |
| Other accrued current liabilities | 36,526 | 47,879 | 44,882 | 35,727 |
| Current portion of operating lease liability | 2,530 | 2,978 | 3,783 | 3,486 |
| Current portion of liability related to sale of future royalties | 1,862 | 1,381 | 2,732 | 2,677 |
| Total current liabilities | 76,842 | 86,754 | 169,300 | 117,878 |
| Operating lease liability, net of current portion | 5,438 | 6,007 | 11,661 | 12,627 |
| Deferred collaboration revenue, net of current portion | 445 | 2,024 | NaN | NaN |
| Liability related to sale of future royalties, net of current portion | 2,372 | 2,679 | 782 | 230 |
| Other long-term liabilities | 841 | 817 | 489 | 472 |
| Total liabilities | 85,938 | 98,281 | 182,232 | 131,207 |
| Common stock 0.0001 par value 350,000,000 shares authorized as of march 31, 2026 and december 31, 2025 242,169,130 shares issued and 241,414,053 shares outstanding as of march 31, 2026 and 240,742,681 shares issued and 240,494,594 shares outstanding as of december 31, 2025 | 24 | 24 | 23 | 23 |
| Additional paid-in capital | 549,613 | 548,131 | 542,346 | 540,328 |
| Treasury stock at cost, 755,077 shares as of march 31, 2026 and 248,087 shares as of december 31, 2025 | 497 | 159 | 371 | 367 |
| Accumulated deficit | -455,016 | -460,195 | -515,240 | -507,099 |
| Accumulated other comprehensive loss | -7 | -3 | -2 | -7 |
| Total stockholders equity | 94,117 | 87,798 | 26,756 | 32,878 |
| Total liabilities and stockholders equity | 180,055 | 186,079 | 208,988 | 164,085 |